As obesity emerges as one of the most critical public health challenges in Türkiye, the treatment landscape is rapidly evolving. This whitepaper examines the key shifts through a holistic lens covering epidemiology, prevention policies, patient journey, and market dynamics. It highlights the expanding role of modern Obesity Medicines such as GLP-1 therapies within the broader obesity management, and reflects on the potential implications of the upcoming loss of exclusivity of semaglutide for treatment continuity and access. The paper brings together data-driven insights to help stakeholders better understand and navigate emerging opportunities and challenges in shaping the future of obesity management in Türkiye.